Le Lézard
Classified in: Covid-19 virus
Subjects: ASI, DEI

Statement - Ministers Ng and Chagger reiterate the Government of Canada's commitment to standing with Asian Canadians against anti-Asian racism


OTTAWA, ON, March 26, 2021 /CNW/ - The Honourable Mary Ng, Minister of Small Business, Export Promotion and International Trade, and the Honourable Bardish Chagger, Minister of Diversity and Inclusion and Youth, today issued the following statement:

"The Government of Canada is committed to standing with Canadians of Asian descent from coast to coast to coast against the drastic rise in anti-Asian racism and hate crimes in Canada. Canada's commitment to inclusion, diversity and multiculturalism is unwavering and offers no place for any forms of racism or discrimination. These harmful acts of anti-Asian racism must stop, and we condemn all forms of it.

"Since the start of the COVID-19 pandemic, we have seen discrimination and violence fuelled by xenophobic rhetoric and scapegoating. As we continue to fight this pandemic and work toward an inclusive recovery, it is important that we remain committed to combatting anti-Asian racism and discrimination in all of its forms to build a society that is consciously more inclusive and safer for all.

"As part of our government's ongoing work to take action against anti-Asian racism, we met today with Asian community and business leaders and allies from Vancouver, Calgary and Edmonton to discuss how the Government of Canada can best support them and collaborate in the fight against anti-Asian racism. Joël Lightbound, Parliamentary Secretary to the Minister of Public Safety and Emergency Preparedness, participated in the discussion on behalf of Minister Blair.

"Minister Joyce Murray and members of Parliament Han Dong, Shaun Chen, Jean Yip, Randeep Sarai, Hedy Fry and Ken Hardie were also present, as well as law enforcement leadership, to hear directly from the community. As a society, as a government and as a country, we must all take action to combat anti-Asian racism and stop the stigma and the spread of misinformation, whether online, on our streets, in our homes or in the workplace.

"No one should ever feel unsafe or threatened because of who they are. As a government, we have a responsibility to take action, and we will continue to work with communities of Asian descent to take concrete steps to confront all forms of anti-Asian racism and discrimination.

"Our work does not stop here. We also call on all Canadians to support and stand with their friends, family and neighbours of Asian descent during these difficult times and to take action against anti-Asian racism."

SOURCE Innovation, Science and Economic Development Canada


These press releases may also interest you

at 02:28
Allied Market Research published a report, titled, "Pet Insurance Market by Policy Coverage (Accident Only, Accident and Illness, and Others), Animal Type (Dogs, Cats, and Others), and Sales Channel (Agency, Broker, and Others): Global...

at 02:00
Bradda Head Lithium Ltd (AIM:BHL), the North America-focused lithium development group, is pleased to announce that it has come to a settlement regarding the fraudulent payment first notified on 29 March 2022 and subsequently disclosed in the audited...

at 00:25
Zai Lab Limited and Innoviva Specialty Therapeutics today announced that China's National Medical Products Administration (NMPA) has approved Zai Lab's New Drug Application (NDA) for XACDURO® (sulbactam-durlobactam) for the treatment of...

19 mai 2024
ICIS, a global source of commodity intelligence, has announced the 16th Asian Base Oils and Lubricants Conference will take place in Singapore, 27-28 June 2024. The event offers a platform for senior executives to connect with peers, potential...

19 mai 2024
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

19 mai 2024
Amgen and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood...



News published on and distributed by: